Pfizer Shares Fall 171 on 12B Volume Ranking 72nd as Oncology Delays and Consumer Revenue Pressures Weigh

On October 9, 2025, , , ranking 72nd in market activity. The drop followed a mixed trading session amid ongoing uncertainty about the pharmaceutical giant's mid-term guidance and regulatory developments in its key therapeutic areas.

Analysts noted that investor sentiment was tempered by recent updates on the company's oncology pipeline, which saw delayed trial results for its experimental breast cancer drug. While the FDA maintained its approval timeline for the therapy, the postponement raised questions about potential market share competition in the high-growth oncology segment. Additionally, mixed performance from its consumer healthcare division, which reported softer-than-expected Q3 revenue, contributed to the downward pressure on shares.

Market participants also observed a broader sell-off in healthcare sector ETFs, . However, institutional buyers remained active in Pfizer's stock, . , suggesting limited near-term bearish pressure despite the recent decline.

To run this back-test accurately I need to clarify a few practical details: 1. Universe - Which market/universe should be scanned each day? (e.g., all U.S. listed common stocks, only S&P-500 constituents, or another list) 2. Volume definition - Do you want to rank by dollar trading value (Price × Shares traded) or by raw share volume? 3. Execution prices - Open the position at the next day’s open and close at that day’s close? - or buy at today’s close and sell at tomorrow’s close? 4. Transaction cost assumptions (commissions, slippage) – if any. With those four items confirmed I can generate the daily trading signals and run the portfolio-level back-test from 2022-01-01 through today.